S'abonner

Fractional exhaled nitric oxide and mortality in asthma and chronic obstructive pulmonary disease in a national cohort aged 40 years and older - 07/06/22

Doi : 10.1016/j.rmed.2022.106879 
Isaac Ikwu a, , Louis Gardy Nicolas b , Alem Mehari c , Richard F. Gillum b
a Pulmonary Disease, Howard University Hospital, 2041 Georgia Ave NW, Washington, DC, 20060USA 
b Howard University College of Medicine, 520 W St, NW, Washington, DC, 20059, USA 
c Howard University College of Medicine, 2041 Georgia Ave NW, Washington, DC, 20060, USA 

Corresponding author.

Abstract

Background

Little is known about Fractional concentration of exhaled Nitric Oxide (FeNO) as a predictor of mortality in persons with asthma or chronic obstructive pulmonary disease (COPD).

Objective

This study tested the hypotheses that FeNO level ≥ 25 ppb was associated with mortality in a national cohort of persons with asthma or COPD age ≥ 40 years.

Methods

In the 2007–2012 National Health and Nutrition Examination Survey (NHANES), FeNO was measured using an electrochemical sensor. Mortality was determined through 2015 using linkage to the National Death Index. Weighted Cox proportional hazards survival analysis was performed taking the complex survey design into account using STATA V.17.

Results

Among the 611 participants with current asthma, 5.16% died during the follow-up period. FeNO ≥ 25 ppb was associated with a hazard ratio (HR) of 0.20, (p = 0.006, 95% CI:0.068–0.618) alone or with little change after controlling for confounding variables. Due to effect modification, the analysis was repeated in persons with and without a history of emergency department (ED) visit for asthma in the previous year. In 522 persons without ED visits, FeNO ≥ 25 ppb was significantly associated with mortality HR 0.094, 95 CI 0.034–0.26, p < 0.001. In 83 persons with ED visits no significant association remained after controlling for all confounders. (Six persons were omitted from this analysis due to missing data on confounders in the extended regression model.) Among 614 with COPD, FeNO ≥ 25 ppb was not associated with mortality.

Conclusion

In persons with current asthma at baseline, FeNO ≥ 25 ppb was associated with reduced hazard of mortality during follow up among those with no history of ED visits in the previous year. No significant association of FeNO with mortality was seen in persons with COPD.

Le texte complet de cet article est disponible en PDF.

Highlights

Study tested hypotheses FeNO level ≥ 25 ppb was associated with mortality in a cohort with asthma and COPD age ≥ 40 years.
Among 611 participants with current asthma, 5.16% died during follow-up period.
In current asthma and no ED visits, FeNO ≥ 25 ppb was associated with mortality HR 0.094, 95 CI 0.034–0.26, p < 0.001.
Among 614 with COPD, FeNO ≥ 25 ppb was not associated with mortality.
Further observational cohort studies with larger numbers of deaths are needed.

Le texte complet de cet article est disponible en PDF.

Keywords : Fractional exhaled nitric oxide, Asthma, COPD, Mortality


Plan


© 2022  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 198

Article 106879- juillet 2022 Retour au numéro
Article précédent Article précédent
  • Identifying asthma patients at high risk of exacerbation in a routine visit: A machine learning model
  • Tianze Jiao, Mireille E. Schnitzer, Amélie Forget, Lucie Blais

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.